BMRN:NSD-Biomarin Pharmaceutical Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 71.02

Change

-0.14 (-0.20)%

Market Cap

USD 13.58B

Volume

1.72M

Analyst Target

USD 111.27
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a once daily injection analog of c-type natriuretic peptide (CNP) for the treatment of achondroplasia; NAGLAZYME, a recombinant form of N- acetylgalactosamine 4-sulfatase for patients with MPS VI; and PALYNZIQ, a PEGylated recombinant phenylalanine (Phe) ammonia lyase enzyme delivered through subcutaneous injection to reduce blood Phe concentrations. It also develops BRINEURA, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; ALDURAZYME, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase; KUVAN, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria, an inherited metabolic disease; and ROCTAVIAN, an adeno associated virus vector for the treatment of severe hemophilia A. The company's products under development include BMN 333, a longer-acting CNP for the treatment of multiple growth disorders, such as achondroplasia and hypochondroplasia; BMN 349, an oral therapeutic for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; and BMN 351, an oligonucleotide for the treatment of duchenne muscular dystrophy. It serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers. The company has license and collaboration agreements with Catalyst Pharmaceutical Partners, Inc., and Ares Trading S.A. The company was incorporated in 1996 and is based in San Rafael, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-03 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+3.52 (+0.73%)

USD 123.21B
REGN Regeneron Pharmaceuticals Inc

-13.87 (-1.99%)

USD 76.39B
ARGX argenx NV ADR

-2.06 (-0.33%)

USD 40.41B
ALNY Alnylam Pharmaceuticals Inc

-3.22 (-1.30%)

USD 31.94B
ONC BeiGene, Ltd.

-26.27 (-9.67%)

USD 25.62B
RPRX Royalty Pharma Plc

+0.22 (+0.65%)

USD 18.65B
SMMT Summit Therapeutics PLC

-1.56 (-7.54%)

USD 17.01B
UTHR United Therapeutics Corporatio..

-10.02 (-3.13%)

USD 14.37B
INCY Incyte Corporation

-3.24 (-4.41%)

USD 14.22B
INSM Insmed Inc

-5.26 (-6.45%)

USD 13.70B

ETFs Containing BMRN

GN0M:XETRA Global X Genomics & Biote.. 3.83 % 0.00 %

-0.12 (-1.48%)

USD 7.05M
GNOM:SW Global X Genomics & Biote.. 3.83 % 0.00 %

-0.09 (-1.48%)

USD 9.42M
GNOG:LSE Global X Genomics & Biote.. 3.69 % 0.00 %

-0.09 (-1.48%)

USD 9.42M
BTEC:SW iShares Nasdaq US Biotech.. 1.63 % 0.00 %

-0.01 (-1.48%)

N/A
SPX4:LSE SPDR® S&P 400 US Mid Cap.. 0.59 % 0.00 %

-0.50 (-1.48%)

N/A
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

+0.67 (+-1.48%)

USD 3.30M
IJJ iShares S&P Mid-Cap 400 V.. 0.00 % 0.25 %

-2.53 (-1.48%)

USD 8.59B
IVOV Vanguard S&P Mid-Cap 400 .. 0.00 % 0.20 %

-1.85 (-1.48%)

USD 0.94B
LABD Direxion Daily S&P Biotec.. 0.00 % 1.00 %

+0.77 (+-1.48%)

USD 0.06B
LABS 0.00 % 0.45 %

N/A

N/A
LABU Direxion Daily S&P Biotec.. 0.00 % 1.14 %

-8.59 (-1.48%)

USD 0.77B
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

-1.22 (-1.48%)

N/A
FCVT First Trust SSI Strategic.. 0.00 % 0.95 %

-0.43 (-1.48%)

USD 0.10B
EASI 0.00 % 0.75 %

N/A

N/A
GNOM Global X Genomics & Biote.. 0.00 % 0.00 %

-0.35 (-1.48%)

USD 0.07B
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.04 (+-1.48%)

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

-0.03 (-1.48%)

N/A
BIGT:LSE L&G Pharma Breakthrough U.. 0.00 % 0.00 %

-2.40 (-1.48%)

N/A
BIOT:LSE L&G PHARMA BREAKTHROUGH G.. 0.00 % 0.00 %

+0.06 (+-1.48%)

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

+0.03 (+-1.48%)

N/A
UBIO 0.00 % 0.95 %

N/A

N/A
ZBIO Zenas BioPharma, Inc. Com.. 0.00 % 0.95 %

-0.37 (-1.48%)

N/A
SPY4:LSE SPDR® S&P 400 US Mid Cap.. 0.00 % 0.00 %

+0.12 (+-1.48%)

N/A
DBPG:F Xtrackers - S&P 500 2x Le.. 0.00 % 0.00 %

-1.00 (-1.48%)

N/A
ETLI:F Legal & General UCITS ETF.. 0.00 % 0.00 %

+0.23 (+-1.48%)

N/A
SPY4:F SSgA SPDR S&P 400 US Mid .. 0.00 % 0.00 %

N/A

N/A
ETLI:XETRA L&G Pharma Breakthrough U.. 0.00 % 0.00 %

-0.03 (-1.48%)

USD 0.02B
BIOT 0.00 % 0.00 %

N/A

N/A
BIOT:SW L&G Pharma Breakthrough U.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 8.05% 81% B- 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 8.05% 81% B- 82% B
Trailing 12 Months  
Capital Gain -19.04% 68% D+ 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -19.04% 68% D+ 37% F
Trailing 5 Years  
Capital Gain -26.67% 68% D+ 35% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.67% 68% D+ 32% F
Average Annual (5 Year Horizon)  
Capital Gain -2.62% 47% F 31% F
Dividend Return -2.62% 47% F 29% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 16.48% 97% N/A 82% B
Risk Adjusted Return -15.89% 37% F 25% F
Market Capitalization 13.58B 98% N/A 94% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.